The HCV polymerase NS5B is susceptible to allosteric inhibition at four sites that have been exploited by compounds that have shown clinical efficacy. The history of the discovery and optimization of leads acting at each of these sites is discussed. The many clinical candidates that emerged from these efforts are described, together with their impact on emerging regimens of increasing effectiveness.